Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)
G. W. McCaughan; P. A. Thwaites; S. K. Roberts; S. I. Strasser; J. Mitchell; B. Morales; S. Mason; P. Gow; A. Wigg; C. Tallis; G. Jeffrey; J. George; A. J. Thompson; F. C. Parker; P. W. Angus
Author Information: Australian National Liver Transplant Unit
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.